Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protalix BioTherapeutics

1.72
-1.1700-40.48%
Post-market: 1.770.0498+2.90%19:58 EDT
Volume:5.95M
Turnover:11.29M
Market Cap:134.22M
PE:46.93
High:2.39
Open:2.39
Low:1.72
Close:2.89
Loading ...

Balanced Outlook for PLUXEE N.V. Amid Spin-Out Opportunities and Market Challenges

TIPRANKS
·
10 Feb

3 US Penny Stocks With Market Caps Under $400M To Watch

Simply Wall St.
·
06 Feb

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

PR Newswire
·
04 Feb

Protalix price target raised to $15 from $10 at H.C. Wainwright

TIPRANKS
·
03 Feb

PLX: Revisiting the Thesis

Zacks Small Cap Research
·
03 Feb

Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
30 Jan

Kepler Capital Sticks to Its Buy Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
10 Jan

PLUXEE N.V. (PLX) Gets a Hold from UBS

TIPRANKS
·
09 Jan

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

PR Newswire
·
23 Dec 2024

Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
13 Dec 2024

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

PR Newswire
·
09 Dec 2024

Pluri assesses readiness to mass produce PLX-R18

TIPRANKS
·
25 Nov 2024

PLX: Self-Sustaining Rise to Lead in Renal Rare Disease

Zacks Small Cap Research
·
15 Nov 2024

Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

GuruFocus.com
·
15 Nov 2024

Protalix BioTherapeutics Reports Strong Q3 2024 Results

TIPRANKS
·
15 Nov 2024

Protalix: Q3 Earnings Snapshot

Associated Press Finance
·
14 Nov 2024

Protalix BioTherapeutics Q3 2024 GAAP EPS $0.03 Misses $0.06 Estimate, Sales $17.96M Beat $16.26M Estimate

Benzinga
·
14 Nov 2024

Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Dow Jones
·
14 Nov 2024